{"protocolSection":{"identificationModule":{"nctId":"NCT02013206","orgStudyIdInfo":{"id":"MO18660"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy","officialTitle":"An Parallel Phase II Study of Tarceva (Erlotinib) in Patients With Advanced Non-small Cell Lung Cancer (Stage IIIB/IV) Not Pre-treated by Chemotherapy Including Dose Escalation to Toxicity in Current and Former Smokers"},"statusModule":{"statusVerifiedDate":"2014-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-09"},"primaryCompletionDateStruct":{"date":"2010-10","type":"ACTUAL"},"completionDateStruct":{"date":"2010-10","type":"ACTUAL"},"studyFirstSubmitDate":"2013-12-11","studyFirstSubmitQcDate":"2013-12-11","studyFirstPostDateStruct":{"date":"2013-12-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-12-12","resultsFirstSubmitQcDate":"2014-12-12","resultsFirstPostDateStruct":{"date":"2014-12-19","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-12-12","lastUpdatePostDateStruct":{"date":"2014-12-19","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will evaluate the efficacy and safety of Tarceva in two groups of patients with non-small cell lung cancer who have not been pre-treated with chemotherapy. One group, consisting of patients who have never smoked, will receive Tarceva 150 mg/day, and the other group, consisting of current/former smokers, will receive Tarceva 150 mg/day increasing to a maximum of 300 mg/day. The anticipated time on study treatment is 1-2 years."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":52,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Never Smokers","type":"EXPERIMENTAL","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity.","interventionNames":["Drug: erlotinib [Tarceva]"]},{"label":"Current/Former Smokers","type":"EXPERIMENTAL","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity.","interventionNames":["Drug: erlotinib [Tarceva]"]}],"interventions":[{"type":"DRUG","name":"erlotinib [Tarceva]","description":"Erlotinib tablets taken orally once daily in the morning.","armGroupLabels":["Current/Former Smokers","Never Smokers"],"otherNames":["Tarceva"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Non-Progression Rate (NPR) at 8 Weeks","description":"Non-Progressive Rate (NPR) was defined as the percentage of participants without progression (had stable disease (SD) or better) based on (Response Evaluation Criteria in Solid Tumours (RECIST) criteria 8 weeks after start of treatment. Diagnosis of Progressive Disease (PD) was made by objective criteria (RECIST criteria) on the target lesion(s), or by documenting, with Computerised Tomography/Magnetic Resonance Imaging (CT/MRI) scans, the presence of newly occurring lesion(s) arising outside the scanned areas of the target lesions. PD required at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","timeFrame":"Week 8"}],"secondaryOutcomes":[{"measure":"Objective Response Rate","description":"Objective response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST). The best overall response was the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). The patient's best response assignment depended on the achievement of both measurement and confirmation criteria. To be assigned the status of PR or CR, changes in tumour measurements were to be confirmed by repeated assessments no less than 4 weeks after the criteria for response were first met.\n\nCR was defined as the disappearance of all target lesions; for non-target lesions disappearance of lesions and normal tumour marker levels. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, using as reference the Baseline sum LD.","timeFrame":"Up to 2 years"},{"measure":"Disease Control Rate","description":"Disease Control Rate was defined as the percentage of participants with Complete Response (CR), Partial Response (PR) or Stable Disease (SD) by Response Evaluation Criteria in Solid Tumours (RECIST). CR was defined as the disappearance of all target lesions; for non-target lesions disappearance of lesions and normal tumour marker levels. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, using as reference the Baseline sum LD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started; for non-target lesions persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.","timeFrame":"Up to 2 years"},{"measure":"Duration of Response","description":"Duration of overall response was defined as the time in months from Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) until the first date Progressive Disease (PD) was objectively documented (taking as reference for PD the smallest measurements recorded since the treatment started) or until the date of death. CR was defined as the disappearance of all target lesions; for non-target lesions disappearance of lesions and normal tumour marker levels.PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, using as reference the Baseline sum LD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","timeFrame":"Up to 2 years"},{"measure":"Time to Progression","description":"Time to progression was defined as the time from start of treatment until the first date criteria for Progressive Disease (PD) was met (taking as reference the smallest measurements recorded since the treatment started). Diagnosis of PD was made by objective criteria (RECIST criteria) on the target lesion(s), or by documenting, with Computerised Tomography/Magnetic Resonance Imaging (CT/MRI) scans, the presence of newly occurring lesion(s) arising outside the scanned areas of the target lesions. PD required at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","timeFrame":"Up to 2 years"},{"measure":"Progression-Free Survival","description":"Progression-Free Survival (PFS) was defined as the time in months from the start of treatment until the first date criteria for Progressive Disease (PD) were met (taking as reference the smallest measurements recorded since the treatment started), or the date of death for any reason in the absence of PD. Diagnosis of PD was made by objective criteria (RECIST criteria) on the target lesion(s), or by documenting, with Computerised Tomography/Magnetic Resonance Imaging (CT/MRI) scans, the presence of newly occurring lesion(s) arising outside the scanned areas of the target lesions.","timeFrame":"Up to 2 years"},{"measure":"Overall Survival","description":"Overall survival was defined as the time in months from the start of treatment to the date of death irrespective of the cause of death.","timeFrame":"Up to 2 years"},{"measure":"Safety: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)","description":"An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.","timeFrame":"Up to 2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* histologically documented advanced non-small cell lung cancer (stage IIIB/IV);\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2;\n* no previous chemotherapy.\n\nExclusion Criteria:\n\n* previous therapy which acts on Epidermal Growth Factor Receptor (EGFR) axis;\n* clinical evidence of brain metastasis;\n* any unstable systemic disease;\n* unable to take oral medication;\n* any significant ophthalmological abnormality.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_CHAIR"}],"locations":[{"city":"Marseille","zip":"13274","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"city":"Hamburg","zip":"22045","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"city":"Milan","zip":"20162","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"city":"Rozzano","zip":"20089","country":"Italy","geoPoint":{"lat":45.38193,"lon":9.1559}},{"city":"Amsterdam","zip":"1105 AZ","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"city":"Maastricht","zip":"6229 HX","country":"Netherlands","geoPoint":{"lat":50.84833,"lon":5.68889}},{"city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"city":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"city":"Manchester","zip":"M2O 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"FG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"23"}]},{"type":"Received Study Drug","achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"23"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"3 Patients were on-going at clinical cut-off. Not Completed=patients who discontinued treatment.","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"22"}]}],"dropWithdraws":[{"type":"Progressive disease (PD)","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"Symptomatic deterioration","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Patient refusal","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Patient non-compliance","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Other reasons off treatment","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"BG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"52"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64","lowerLimit":"38","upperLimit":"83"},{"groupId":"BG001","value":"66","lowerLimit":"42","upperLimit":"88"},{"groupId":"BG002","value":"65","lowerLimit":"38","upperLimit":"88"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"34"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"18"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Non-Progression Rate (NPR) at 8 Weeks","description":"Non-Progressive Rate (NPR) was defined as the percentage of participants without progression (had stable disease (SD) or better) based on (Response Evaluation Criteria in Solid Tumours (RECIST) criteria 8 weeks after start of treatment. Diagnosis of Progressive Disease (PD) was made by objective criteria (RECIST criteria) on the target lesion(s), or by documenting, with Computerised Tomography/Magnetic Resonance Imaging (CT/MRI) scans, the presence of newly occurring lesion(s) arising outside the scanned areas of the target lesions. PD required at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","populationDescription":"Intent-to-Treat Population included all registered participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.4","lowerLimit":"23.5","upperLimit":"61.1"},{"groupId":"OG001","value":"65.2","lowerLimit":"42.7","upperLimit":"83.6"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate","description":"Objective response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST). The best overall response was the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). The patient's best response assignment depended on the achievement of both measurement and confirmation criteria. To be assigned the status of PR or CR, changes in tumour measurements were to be confirmed by repeated assessments no less than 4 weeks after the criteria for response were first met.\n\nCR was defined as the disappearance of all target lesions; for non-target lesions disappearance of lesions and normal tumour marker levels. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, using as reference the Baseline sum LD.","populationDescription":"Intent-to-Treat Population included all registered participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","lowerLimit":"5.9","upperLimit":"35.8"},{"groupId":"OG001","value":"35","lowerLimit":"16.4","upperLimit":"57.3"}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate","description":"Disease Control Rate was defined as the percentage of participants with Complete Response (CR), Partial Response (PR) or Stable Disease (SD) by Response Evaluation Criteria in Solid Tumours (RECIST). CR was defined as the disappearance of all target lesions; for non-target lesions disappearance of lesions and normal tumour marker levels. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, using as reference the Baseline sum LD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started; for non-target lesions persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.","populationDescription":"Intent-to-Treat Population included all registered participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","lowerLimit":"23.5","upperLimit":"61.1"},{"groupId":"OG001","value":"65","lowerLimit":"42.7","upperLimit":"83.6"}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of overall response was defined as the time in months from Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) until the first date Progressive Disease (PD) was objectively documented (taking as reference for PD the smallest measurements recorded since the treatment started) or until the date of death. CR was defined as the disappearance of all target lesions; for non-target lesions disappearance of lesions and normal tumour marker levels.PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, using as reference the Baseline sum LD. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","populationDescription":"Participants from the Intent-to-Treat (ITT) Population, that included all participants, with CR or PR. Patients still responding to treatment at the time of analysis were treated as censored observations for duration of response on the date of the last tumour assessment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","lowerLimit":"4.6","upperLimit":"13.1"},{"groupId":"OG001","value":"5.7","lowerLimit":"4.0","upperLimit":"NA","comment":"95% Confidence Interval Upper limit was not estimated due to the small number of participants."}]}]}]},{"type":"SECONDARY","title":"Time to Progression","description":"Time to progression was defined as the time from start of treatment until the first date criteria for Progressive Disease (PD) was met (taking as reference the smallest measurements recorded since the treatment started). Diagnosis of PD was made by objective criteria (RECIST criteria) on the target lesion(s), or by documenting, with Computerised Tomography/Magnetic Resonance Imaging (CT/MRI) scans, the presence of newly occurring lesion(s) arising outside the scanned areas of the target lesions. PD required at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.","populationDescription":"Safety Population included all registered patients who received at least 1 dose of study treatment and had at least 1 safety follow-up. Patients without PD at the time of analysis were censored on the date of the last tumour assessment. Patients without PD who received a second anti-cancer therapy were censored prior to start of new therapy.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"1.0","upperLimit":"5.6"},{"groupId":"OG001","value":"5.5","lowerLimit":"3.4","upperLimit":"7.3"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival","description":"Progression-Free Survival (PFS) was defined as the time in months from the start of treatment until the first date criteria for Progressive Disease (PD) were met (taking as reference the smallest measurements recorded since the treatment started), or the date of death for any reason in the absence of PD. Diagnosis of PD was made by objective criteria (RECIST criteria) on the target lesion(s), or by documenting, with Computerised Tomography/Magnetic Resonance Imaging (CT/MRI) scans, the presence of newly occurring lesion(s) arising outside the scanned areas of the target lesions.","populationDescription":"Safety Population included all registered participants who received at least one study treatment and had at least one safety follow-up. Patients without PD at the time of analysis were censored on the date of the last tumour assessment. Patients without PD who received a second anti-cancer therapy were censored prior to start of new therapy.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"1.0","upperLimit":"5.6"},{"groupId":"OG001","value":"4.1","lowerLimit":"3.4","upperLimit":"5.7"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the time in months from the start of treatment to the date of death irrespective of the cause of death.","populationDescription":"Safety Population included all participants with at least one study treatment and had at least one safety follow-up. Patients who had not died at the time of the final analysis were censored at the date of last contact.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","lowerLimit":"5.6","upperLimit":"14.0"},{"groupId":"OG001","value":"13.9","lowerLimit":"8.9","upperLimit":"18.0"}]}]}]},{"type":"SECONDARY","title":"Safety: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)","description":"An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.","populationDescription":"Safety Population included all registered participant who received at least one study treatment and had at least one safety follow-up.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity."},{"id":"OG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"23"}]}],"classes":[{"title":"Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"23"}]}]},{"title":"Serious Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"4","timeFrame":"Up to 2 Years","eventGroups":[{"id":"EG000","title":"Current/Former Smokers","description":"Current Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and either quit smoking \\< 1 year ago or were currently smoking) or Former Smokers (participants who smoked \\> 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib \\[Tarceva\\] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity.","seriousNumAffected":14,"seriousNumAtRisk":26,"otherNumAffected":26,"otherNumAtRisk":26},{"id":"EG001","title":"Never Smokers","description":"Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib \\[Tarceva\\] 150 mg orally daily until disease progression or unacceptable toxicity.","seriousNumAffected":7,"seriousNumAtRisk":23,"otherNumAffected":23,"otherNumAtRisk":23}],"seriousEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Pseudomonas infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Tumour necrosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Anuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Ovarian disorder","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Biopsy muscle","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Dry Eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Growth of eyelashes","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":26},{"groupId":"EG001","numAffected":11,"numAtRisk":23}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":26},{"groupId":"EG001","numAffected":11,"numAtRisk":23}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":26},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":26},{"groupId":"EG001","numAffected":8,"numAtRisk":23}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":26},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Hepatobiliary disorders","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Injury, poisoning and procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":26},{"groupId":"EG001","numAffected":7,"numAtRisk":23}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":26},{"groupId":"EG001","numAffected":12,"numAtRisk":23}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":26},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Reproductive system and breast disorders","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":26},{"groupId":"EG001","numAffected":3,"numAtRisk":23}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":26},{"groupId":"EG001","numAffected":0,"numAtRisk":23}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":26},{"groupId":"EG001","numAffected":7,"numAtRisk":23}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":26},{"groupId":"EG001","numAffected":5,"numAtRisk":23}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":26},{"groupId":"EG001","numAffected":8,"numAtRisk":23}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":26},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":26},{"groupId":"EG001","numAffected":4,"numAtRisk":23}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":26},{"groupId":"EG001","numAffected":19,"numAtRisk":23}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Trichomegaly","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Mucosal dryness","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Skin toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]},{"term":"Surgical and medical procedures","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":26},{"groupId":"EG001","numAffected":2,"numAtRisk":23}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26},{"groupId":"EG001","numAffected":1,"numAtRisk":23}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Treatment was ongoing for 3 patients at the time of the Clinical Study Report (CSR) cut-off. In the addendum to the CSR, there were no findings for these 3 patients that deviated from those observed in the original report."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffman-LaRoche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}